FOLD
HealthcareAmicus Therapeutics, Inc.
$14.25
$-0.02 (-0.14%)
Jan 5, 2026
Price History (1Y)
Analysis
Amicus Therapeutics, Inc. is a biotechnology company in the healthcare sector, with a market capitalization of $4.41B. It has 499 employees and operates within the industry of biotechnology. Financially, Amicus Therapeutics has reported revenue of $598.70M over the trailing twelve months (TTM), with an EBITDA of $42.12M and free cash flow of $38.40M. The company's gross margin stands at 89.8%, while its operating margin is 20.3%. However, it has reported a net loss of $14,061,000 over the TTM period. Amicus Therapeutics has a significant amount of debt, totaling $442.82M, but also holds $263.84M in cash. The company's valuation metrics are as follows: forward P/E ratio of 22.01 and price to sales ratio of 7.36. Revenue growth over the past year (YoY) has been 19.5%. The dividend yield is not available for this company, with a payout ratio of 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Visit website →Key Statistics
- Market Cap
- $4.41B
- P/E Ratio
- N/A
- 52-Week High
- $14.36
- 52-Week Low
- $5.51
- Avg Volume
- 9.01M
- Beta
- 0.41
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 499